

Amikar Sehdev, M.D., M.P.H., F.A.C.P.

Ironwood Cancer and Research Centers

Division of Oncology and Hematology

Gastrointestinal, Skin & Sarcoma Malignancies

Education:

07/97-12/02	Bachelor of Medicine and Bachelor of Surgery (M.B.B.S.), Government Medical College and Hospital (GMCH), Chandigarh, India
01/03-06/03	House Officer, Department of Psychiatry, Government Medical College and Hospital (GMCH), Chandigarh, India
07/03-07/04	House Officer, Verma Maternity Center, Panchkula, India
08/04-06/07	Masters of Public Health (M.P.H.), Northern Illinois University (NIU), DeKalb, IL
07/07-06/10	Internal Medicine Residency, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
07/10-06/11	Instructor, Department of Medicine, University of Utah, Salt Lake City, UT
07/11-06/14	Fellow, Hematology Oncology, University of Chicago, Chicago, IL
07/13-08/13	Fellow, AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, CO
03/13-03/14	Bioinformatics, Center for Research Informatics, University of Chicago, Chicago, IL
2013-2014	Coursework in Translational Bioinformatics, Stanford University, Stanford, CA

Professional Experience:

6/2020 – Present	Physician, Ironwood Cancer & Research Centers, Glendale, AZ
2014-6/20	Assistant Professor of Clinical Medicine, Division of Hematology Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
10/14-6/20	Adjunct Faculty, Richard M. Fairbanks School of Public Health, Indiana University

Amikar Sehdev, M.D., M.P.H., F.A.C.P.

10/14-6/20 Regenstrief Affiliated Scientist, Regenstrief Institute, Indianapolis, IN

7/10-6/11 Instructor, Department of Medicine, University of Utah, Salt Lake City, UT

Activities and Honors:

Certifications:

American Board of Internal Medicine- Oncology

American Board of Internal Medicine

ABIM- Hematology

Awards, Honors and Committees:

Preceptor, Midwestern University, Glendale, AZ

Technology Research Group Committee member

Reviewer, Scientific Review Committee, Indiana University

Indiana Oncology Society, Board Member-at-Large

Scientific Advisory Board, Eli Lilly and Company

American Society of Clinical Oncology

ASCO melanoma guidelines committee member

ASCO Reading Room committee member and Journal and Peer Reviewers Group

Scientific Advisory Board, Incyte Corporation/Cardinal Health

Scientific Advisory Board, Eisai Inc.

Scientific Advisory Board, Array BioPharma

Director of the Pancreatic Cancer Program, Indiana University, 06/19-06/20

Heroes Foundation SJP Scholar, Heroes Foundation, 2016

Illinois Medical Oncology Society Fellows Research Competition Winner, 2013

Clinical and Translational Science Award, University of Chicago, Chicago, IL, 2012

Kozloff Fellow of the Year 2012

Professional Memberships:

American Society of Clinical Oncology

American Society of Hematology

American Medical Association (AMA)

American College of Physicians (ACP)

Publications:

Peer-reviewed publications in the primary literature, exclusive of abstracts:

1. Fichera A, **Sehdev A**, Bissonnette M, et al. EGFR Signaling is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis. *Cancer Research*. 2007 Jan; 67(2): 827-835
2. Dougherty U, **Sehdev A**, Bissonnette M, et al. EGFR Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model. *Clinical Cancer Research*. 2008 Apr; 14(8): 2253-62
3. Dougherty U, **Sehdev A**, Bissonnette M, et al. EGFR is Required for Colonic Tumor Promotion by Dietary Fat in the Azoxymethane/Dextran Sulfate Sodium Model: Roles of TGF- α and PTGS2. *Clinical Cancer Research*. 2009 Nov; 15(22): 6780-6789
4. **Sehdev A** and Dhoble A. Pulmonary Artery Dissection: A Very Unusual Cause of Chest Pain. *Journal of Hospital Medicine*. 2010 May; 5(5): 313-316
5. Lash A, **Sehdev A** and Plonczynski D. Trends in Hypothesis Testing and Related Variables in Nursing Research: a Retrospective Exploratory Study. 2011; 18 (3): 38-44
6. **Sehdev A**, Wanner N, Pendleton RC. Statins for the Prevention of Venous Thromboembolism? A Narrative Review. *Hosp Pract (Minneap)*. 2012 Aug;40(3):13-8
7. **Sehdev A**, Zhao Y, Singh AK and Sharma N. Primary Small Cell Carcinoma of the Tonsil: A Case Report and Review of the Literature. *Case Rep Oncol*. 2012 Sep;5(3):537-41
8. **Sehdev A** and Catenacci DVT: Gastroesophageal Cancer: Focus on Epidemiology, Classification and Staging. *Discovery Medicine* 2013, 16(87):103–111
9. **Sehdev A** and Catenacci DVT: Perioperative Therapy for Locally Advanced Gastroesophageal Cancer: Current Controversies and Consensus of Care. *Journal of Hematology & Oncology* 2013, Sep 5;6(1):66
10. **Sehdev A** and Polite BP: Modern Chemoradiation and Chemotherapy Protocols for Locally Advanced Rectal Cancer: The Current and Future Standards of Care. *Seminars in Colon and Rectal Surgery* 2013, 24(3):132-141
11. **Sehdev A**, Shih T, Vekhter B, Lyttle C, Huo D and Polite BP: The Role of Statins for Primary Prevention in Non-elderly Colorectal Cancer Patients. *Anticancer Research* 2014, 34(9): 1-8
12. **Sehdev A**, Shih T, Vekhter B, Bissonnette MB, Olopade OI and Polite BP. Metformin for Primary Colorectal Cancer Prevention in Diabetic Patients: A Case-Control Study in a US Population. *Cancer* 2014, Nov 25

13. Valsangkar N, **Sehdev A**, Misra S, Zimmers TA, O'Neil BH, and Koniaris LG. Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy. *Surgery*, June 2015
14. **Sehdev A** and O'Neil BH. The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer. *Current Treatment Options in Oncology*. September 2015, 16:43
15. **Sehdev A**, Cramer H, Ibrahim AA, Younger AE and O'Neil BH. Pathological Complete Response with Anti-PD1 Therapy in a Patient with Microsatellite Instable High, BRAF Mutant Metastatic Colon Cancer: A Case Report and Review of Literature. *Discovery Medicine*. May 22, 2016
16. **Sehdev A**, Sherer EA, Hui SL, Wu J and Haggstrom DA. Patterns of computed tomography surveillance in survivors of colorectal cancer at Veterans Health Administration facilities. *Cancer*, 2017 Jun 15;123(12):2338-2351
17. Mamdani H, Wu Howard, O'Neil BH and **Sehdev A**. Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma: Case Report and Review of Literature. *Discovery Medicine* 2017, May;23(128):331-336
18. Dadi N, Stanley M, Shahda S, O'Neil BH and **Sehdev A**. Impact of Nab–Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. *Anticancer Research* October 2017 vol. 37 no. 10 5533-5539
19. **Sehdev A**, Karrison T, Zha Y, Sharma MR et al. A Pharmacodynamic Study of Sirolimus and Metformin in Patients with Advanced Solid Tumors. *Cancer Chemother Pharmacol*. 2018 Aug;82(2):309-317
20. **Sehdev A**, Gbolahan O, Hancock BA, O'Neil BH et al. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. *Clinical Cancer Research*. DOI: 10.1158/1078-0432.CCR-18-1472
21. DeWitt JM, Sandrasegaran K, O'Neil B, House MG, Zyromski NJ, **Sehdev A**, Perkins SM, Flynn J, McCranor L, Shahda S. Phase I Study of EUS-guided Photodynamic Therapy for Locally Advanced Pancreatic Cancer. *Gastrointest Endosc*. 2018 Sep 14 [Epub ahead of print]
22. Milgrom DP, **Sehdev A**, Kays JK, Koniaris LG. Integrating therapies for surgical adult soft tissue sarcoma patients. *Translational Gastroenterology and Hepatology* 2018, 3:88
23. Gbolahan OB, Tong Y, **Sehdev A**, O'Neil BH, Shahda S. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. *BMC Cancer*. 2019 May; 19 (1): 468
24. Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, **Sehdev A** et al. 5-fluorouracil/leucovorin, nab-paclitaxel, and irinotecan with UGT1A1 genotype-guided dosing (FOLFIRABRAX) in untreated patients with gastrointestinal malignancies. Accepted in *Clinical Cancer Research* July 24, 2019
25. Patel AS, Snook RJ, Sehdev A. Chronic Inflammatory Demyelinating Polyradiculoneuropathy Secondary to Immune Checkpoint Inhibitors in Melanoma Patients. *Discovery Medicine* 2019, Aug; 28(152)

Book chapters:

- Sehdev A** and Marsh R. Contribution of Chemotherapy to the Toxicity of Pelvic Irradiation. Book Chapter. *Radiation Therapy for Pelvic Malignancy and its Consequences*. Editors, Ehrenpreis, Marsh and Small. Publisher, Springer. Publication date, August 2014

Non-peer-reviewed original articles

1. **Sehdev, A.** Genetics and Cancer Prevention: Focus on Colorectal Cancer. Website: <http://biochem158.stanford.edu/Final%20Papers%202013/Sehdev.pdf>
2. **Sehdev, A.** ASCO MedPage Today Expert Critique. Melanoma Gene-expression Biomarker Predicts Immunotherapy Response. Website: <https://www.medpagetoday.com/reading-room/asco/skin-cancer/75813>. Dated Oct 20, 2018
3. **Sehdev, A.** ASCO MedPage Today Expert Critique. Improved Immunotherapy Response in Melanoma Patients with Genetic Mutations. Website: <https://www.medpagetoday.com/reading-room/asco/immunotherapy/76193>. Dated Nov 8, 2018
4. **Sehdev, A.** ASCO MedPage Today Expert Critique. Liquid Biopsy and MSI in Multiple tumors. Website: <https://www.medpagetoday.com/reading-room/asco/immunotherapy/82392>. Dated Sept 9, 2019
5. **Sehdev, A.** ASCO MedPage Today Expert Critique. Long-Term QOL for Melanoma Patients on Immunotherapy. Website: <https://www.medpagetoday.com/reading-room/asco/immunotherapy/83066>. Dated Oct 31, 2019
6. **Sehdev, A.** ASCO MedPage Today Expert Critique. BRAF-Mutated Metastatic Melanoma: Recent Research Context. Website: <https://www.medpagetoday.com/reading-room/asco/skin-cancer/83507>. Dated Nov 23, 2019

PRESENTATIONS

1. PKC-Delta Mediates Pro-Inflammatory Responses in RAW-264.7 Macrophage Cells and Is Down-Regulated in Human Colon Cancer Stromal Cells. Presented at: Digestive Disease Week 2007; Washington, DC
2. EGFR Controls Flat Dysplastic ACF Development and Colon Cancer Progression in the Rat Azoxymethane Model. Presented at: Digestive Disease Week 2008-Poster of Distinction; San Diego, CA
3. A Case of Pulmonary Sequestration. Presented at: American College of Physicians Northern Illinois Meeting; Maywood, IL
4. The Role of Statins for Primary Prevention in Non-elderly Colorectal Cancer Patients. Presented at: 2013 American Society of Clinical Oncology, Annual Meeting, Chicago, IL
5. The Role of Metformin for Primary Prevention in Non-elderly Diabetic Colorectal Cancer Patients. Presented at: 2014 GI Cancers Symposium, San Francisco, CA
6. The Role of Statins for Primary Prevention in Non-Elderly Colorectal Cancer Patients. Presented at: Outcomes Research Workshop, Center for Health and the Social Sciences, University of Chicago, Chicago, IL. 2013.
7. Statins in Colorectal Cancer Patients. Presented at: Illinois Medical Oncology Society Annual Meeting, Chicago, IL. 2013.
8. Metformin: Role as a Potential Chemopreventive and Therapeutic Agent in Colorectal Cancer. Presented at: Washington University, St. Louis, MO. 2014.
9. Metformin: Role as a Potential Chemopreventive and Therapeutic Agent in Colorectal Cancer. Presented at: Indiana University, Indianapolis, IN. 2014.
10. Possible Targets of Metformin in Colorectal Cancer. Presented at: 2014 American Association for

Cancer Research (AACR) Annual Conference on Frontiers in Cancer Prevention Research, New Orleans, LA

11. The Quality of CT Surveillance in Resected Colorectal Cancer survivors at Veterans Health Administration Facilities. Presented at: 2016 Gastrointestinal Cancer Symposium, San Francisco, CA
12. Neoadjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer. Presented at: 2016 AACR Special Conference on Pancreatic Cancer. Orlando, FL
13. Demographic, Clinical and Outcomes Characteristics Associated with Screening Colonoscopy in Colorectal Cancer Patients. Presented at: 2017 Gastrointestinal Cancer Symposium, San Francisco, CA.
14. Impact of Nab-paclitaxel-based Second Line Chemotherapy on the Outcomes of Pancreatic Cancer. Presented at: 2017 Gastrointestinal Cancer Symposium, San Francisco, CA.
15. Survival After Recurrence Following Curative Intent Resection of Pancreatic Adenocarcinoma. Presented at: 2017 American Society of Clinical Oncology, Annual Meeting, Chicago, IL
16. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer. Presented at: 2017 American Society of Clinical Oncology, Annual Meeting, Chicago, IL.
17. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Presented at: 2017 American Society of Clinical Oncology, Annual Meeting, Chicago, IL
18. A Phase Ib/2 study of cancer stemness inhibitor Napabucasin (BBI-608) in combination with Gemcitabine (Gem) & nab-Paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts). Presented at: 2017 ESMO, Barcelona, Spain.
19. The Impact of Research Presented at Annual Gastrointestinal Cancers Symposium. Presented at: 2018 GI Cancers Symposium, San Francisco, CA
20. Prognostic role of BRAF mutation in malignant cutaneous melanoma. Presented at: 2018 American Society of Clinical Oncology, Annual Meeting, Chicago, IL.
21. Safety and tolerability of FOLFIRABRAX [5-Fluorouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium. Presented at: 2018 American Society of Clinical Oncology, Annual Meeting, Chicago, IL.
22. A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Presented at: 2018 American Society of Clinical Oncology, Annual Meeting, Chicago, IL.
23. Association of RAS mutations with Race in Metastatic Colorectal Cancer CALGB 80405 (ALLIANCE). Presented at: 2018 GI Cancers Symposium, San Francisco, CA
24. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Presented at: 2018 ESMO, Munich, Germany.
25. Neoadjuvant therapy duration and outcome of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC). Presented at: 2019 at Annual Gastrointestinal Cancers Symposium, San Francisco, CA

Amikar Sehdev, M.D., M.P.H., F.A.C.P.

Research Trials:

Sub investigator in Ironwood Cancer and Research Centers trials, please refer to website for details.

Other Activities:

Dr. Sehdev enjoys running, reading, photography, playing chess and spending time with his family.